Biogen's S1P Modulator License – A Good Deal Done Too Late?
This article was originally published in Scrip
Biogen's license for the sphingosine 1-phosphate (S1P) receptor modulator MT-1303 from Mitsubishi Tanabe for up to $544m makes a lot of sense, but with four S1P-targeting drugs approved or in late-stage development did Biogen execute a good deal too late to catch up with the competition?
You may also be interested in...
The first round of third-quarter earnings reports for big pharmas quietly featured news about drug discontinuations and failures.
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.
ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment.